Fluzoparib

Drug Profile

Fluzoparib

Alternative Names: SHR 3162

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Fallopian tube cancer; Gastric cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 14 Mar 2017 Jiangsu HengRui Medicine and Beijing Cancer Hospital plan a phase I trial for Ovarian cancer and Breast cancer (Combination therapy, Second-line therapy or greater) in China (NCT03075462)
  • 09 Mar 2017 Phase-I clinical trials in Breast cancer (Combination therapy, Second-line therapy or greater) in China (PO) (NCT03075462)
  • 09 Mar 2017 Phase-I clinical trials in Fallopian tube cancer (Combination therapy, Second-line therapy or greater) in China (PO) (NCT03075462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top